Blueprint to pull Gavreto in certain markets, shelve EGFR programs as it focuses on Ayvakit launch

As Blue­print Med­i­cines braces it­self for a fu­ture with­out a ma­jor Roche col­lab­o­ra­tion, the Mass­a­chu­setts biotech is pulling its RET in­hibitor from cer­tain mar­kets and chop­ping sev­er­al can­cer drug can­di­dates in a pri­or­i­ti­za­tion ex­er­cise.

“Giv­en Blue­print Med­i­cines’ lack of glob­al in­fra­struc­ture in lung and thy­roid can­cer, the com­pa­ny has de­cid­ed to dis­con­tin­ue glob­al de­vel­op­ment and mar­ket­ing of GAVRE­TO in ter­ri­to­ries ex­clud­ing the U.S. and Greater Chi­na,” it wrote in a state­ment, adding that wind-down ac­tiv­i­ties will be­gin this quar­ter. Gavre­to is ap­proved in the Eu­ro­pean Union.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.